These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 21555373)
1. The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model. Sharma AK; Kline CL; Berg A; Amin S; Irby RB Clin Cancer Res; 2011 Jul; 17(13):4474-83. PubMed ID: 21555373 [TBL] [Abstract][Full Text] [Related]
2. The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. Allen JE; Gallant JN; Dicker DT; Amin S; Irby RB; Sharma AK; El-Deiry WS PLoS One; 2013; 8(3):e59380. PubMed ID: 23555026 [TBL] [Abstract][Full Text] [Related]
3. The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU. Kline CL; Irby RB Apoptosis; 2011 Dec; 16(12):1285-94. PubMed ID: 21910008 [TBL] [Abstract][Full Text] [Related]
4. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Wang BD; Kline CL; Pastor DM; Olson TL; Frank B; Luu T; Sharma AK; Robertson G; Weirauch MT; Patierno SR; Stuart JM; Irby RB; Lee NH Mol Cancer; 2010 Apr; 9():98. PubMed ID: 20433755 [TBL] [Abstract][Full Text] [Related]
5. Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Kline CL; Shanmugavelandy SS; Kester M; Irby RB Cancer Biol Ther; 2009 Oct; 8(19):1831-7. PubMed ID: 19729995 [TBL] [Abstract][Full Text] [Related]
6. Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway. Xu J; Zhang S; Wang R; Wu X; Zeng L; Fu Z Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28432271 [TBL] [Abstract][Full Text] [Related]
7. Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation. Morii Y; Tsubaki M; Takeda T; Otubo R; Seki S; Yamatomo Y; Imano M; Satou T; Shimomura K; Nishida S Eur J Pharmacol; 2021 May; 898():173957. PubMed ID: 33662352 [TBL] [Abstract][Full Text] [Related]
8. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. Sun L; Huang Y; Liu Y; Zhao Y; He X; Zhang L; Wang F; Zhang Y Cell Death Dis; 2018 Sep; 9(9):911. PubMed ID: 30185800 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer. Das TP; Suman S; Alatassi H; Ankem MK; Damodaran C Cell Death Dis; 2016 Feb; 7(2):e2111. PubMed ID: 26913603 [TBL] [Abstract][Full Text] [Related]
10. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis. Zhang L; Wang H; Li W; Zhong J; Yu R; Huang X; Wang H; Tan Z; Wang J; Zhang Y Oncotarget; 2017 Jan; 8(2):3289-3303. PubMed ID: 27924057 [TBL] [Abstract][Full Text] [Related]
11. Phenylbutyl isoselenocyanate induces reactive oxygen species to inhibit androgen receptor and to initiate p53-mediated apoptosis in LNCaP prostate cancer cells. Wu W; Karelia D; Pramanik K; Amin SG; Sharma AK; Jiang C; Lu J Mol Carcinog; 2018 Aug; 57(8):1055-1066. PubMed ID: 29668110 [TBL] [Abstract][Full Text] [Related]
12. Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice. Huang M; Tang SN; Upadhyay G; Marsh JL; Jackman CP; Srivastava RK; Shankar S Cancer Lett; 2014 Oct; 353(1):32-40. PubMed ID: 25050737 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of Par-4 sensitizes TRAIL-induced apoptosis via inactivation of NF-kappaB and Akt signaling pathways in renal cancer cells. Lee TJ; Jang JH; Noh HJ; Park EJ; Choi KS; Kwon TK J Cell Biochem; 2010 Apr; 109(5):885-95. PubMed ID: 20127709 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. Zhang Y; Talmon G; Wang J Cell Death Dis; 2015 Aug; 6(8):e1845. PubMed ID: 26247730 [TBL] [Abstract][Full Text] [Related]
15. Idelalisib induces PUMA-dependent apoptosis in colon cancer cells. Yang S; Zhu Z; Zhang X; Zhang N; Yao Z Oncotarget; 2017 Jan; 8(4):6102-6113. PubMed ID: 28008149 [TBL] [Abstract][Full Text] [Related]
16. The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity. Ibáñez E; Agliano A; Prior C; Nguewa P; Redrado M; González-Zubeldia I; Plano D; Palop JA; Sanmartín C; Calvo A Curr Med Chem; 2012; 19(18):3031-43. PubMed ID: 22455594 [TBL] [Abstract][Full Text] [Related]
17. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer. Qazi AK; Hussain A; Khan S; Aga MA; Behl A; Ali S; Singh SK; Taneja SC; Shah BA; Saxena AK; Mondhe DM; Hamid A Cancer Lett; 2015 Apr; 359(1):47-56. PubMed ID: 25554016 [TBL] [Abstract][Full Text] [Related]
18. BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt. Pal I; Sarkar S; Rajput S; Dey KK; Chakraborty S; Dash R; Das SK; Sarkar D; Barile E; De SK; Pellecchia M; Fisher PB; Mandal M Br J Cancer; 2014 Jul; 111(1):101-11. PubMed ID: 24892445 [TBL] [Abstract][Full Text] [Related]
19. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway. Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751 [TBL] [Abstract][Full Text] [Related]
20. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT. Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]